Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
19 Enero 2022 - 10:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of January, 2022
Commission File Number: 001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name into English)
5 Badner St.
Ramat Gan,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
RAMAT GAN,
Israel - (January, 2022) XTL Biopharmaceuticals Ltd. (the “Company”)
announces today the postponement of the annual shareholders' meeting scheduled for January 19, 2022, since legal quorum requirements as
set forth in the meeting’s convening notice were not met.
The Company
has announced that the deferred annual shareholders meeting will reconvene on January 26, 2022, at 3:00PM (Israel Standard Time).
About XTL Biopharmaceuticals Ltd. (XTL)
XTL Biopharmaceuticals Ltd.,
is a clinical-stage biotech company. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment
of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SS). The few treatments currently
on the market for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed
scientific journals.
XTL is traded on the
Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following indices:
Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: ir@xtlbio.com
www.xtlbio.com
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: January 19, 2022
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
By:
|
/s/ Shlomo Shalev
|
|
|
|
Shlomo Shalev
Chief Executive Officer
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
